Clinical Edge Journal Scan

Vacuum-assisted biopsy predicts post-treatment residual disease in breast cancer


 

Key clinical point : Vacuum-assisted biopsy accurately predicted residual disease in breast cancer patients after neoadjuvant chemotherapy.

Major finding: The overall false negative rate using vacuum-assisted biopsy (VAB) was 18.7%; in a subgroup of patients with a complete/partial response and imaging abnormalities of 2 cm or smaller, the false negative rate was 3.2% and the negative predictive value was 97.4% for an overall accuracy of 89.5% with VAB.

Study details : The data come from a diagnostic study of 166 women with breast cancer who received neoadjuvant chemotherapy followed by image-guided biopsy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Citation: Tasoulis MK et al. JAMA Surg. 2020 Oct 7. doi: 10.1001/jamasurg.2020.4103.

Recommended Reading

New estimates for breast cancer risk with HRT
Breast Cancer ICYMI
One-month delay in cancer treatment linked to increase in mortality
Breast Cancer ICYMI
Study supports genetic testing in older women with breast cancer
Breast Cancer ICYMI
New cancer drugs may have saved more than 1.2 million Americans
Breast Cancer ICYMI
‘Test all patients with cancer’: One in eight have inherited mutations
Breast Cancer ICYMI
Pembrolizumab approved for triple-negative breast cancer
Breast Cancer ICYMI
Using telehealth to deliver palliative care to cancer patients
Breast Cancer ICYMI
Pregnancy outcomes ‘favorable’ after BRCA breast cancer treatment
Breast Cancer ICYMI
Black women show higher rates of three breast cancer subtypes
Breast Cancer ICYMI
Immediate breast reconstruction after chemotherapy doesn’t hurt survival
Breast Cancer ICYMI